Trevi Therapeutics, Inc.
12.61USD
-0.3300 (-2.55%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TRVI.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | — | — | — | 0.0 | 0.0 |
| Q1 | — | — | — | — | — | — |
| Q2 | — | — | — | — | — | — |
| Q3 | — | — | — | — | 0.0 | — |
| Q4 | — | — | — | — | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.450 | -.290 | -.470 | -.320 | -.479 | -.577 |
| Q1 | -.120 | -.060 | -.110 | -.090 | -.090 | — |
| Q2 | -.140 | -.070 | -.120 | -.090 | -.110 | — |
| Q3 | -.120 | -.080 | -.130 | -.080 | -.133 | — |
| Q4 | -.085* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.079* |
| -.112* |
| -.062* |
| -.143 |
| — |
Debt level and coverage